Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain
- PMID: 8643438
- PMCID: PMC39311
- DOI: 10.1073/pnas.93.10.4529
Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain
Abstract
Paraneoplastic neurologic disorders (PNDs) are believed to be autoimmune neuronal degenerations that develop in some patients with systemic cancer. A series of genes encoding previously undiscovered neuronal proteins have been cloned using antiserum from PND patients. Identification of these onconeural antigens suggests a reclassification of the disorders into four groups: those in which neuromuscular junction proteins, nerve terminal/vesicle-associated proteins, neuronal RNA binding proteins, or neuronal signal-transduction proteins serve as target antigens. This review considers insights into basic neurobiology, tumor immunology, and autoimmune neuronal degeneration offered by the characterization of the onconeural antigens.
Similar articles
-
Mouse chromosomal locations of nine genes encoding homologs of human paraneoplastic neurologic disorder antigens.Genomics. 1997 Oct 15;45(2):313-9. doi: 10.1006/geno.1997.4925. Genomics. 1997. PMID: 9344654
-
[Mechanisms of paraneoplastic neurologic syndromes].Rev Med Interne. 1999 Aug;20(8):670-80. doi: 10.1016/s0248-8663(99)80487-1. Rev Med Interne. 1999. PMID: 10480170 Review. French.
-
Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration.Annu Rev Neurosci. 2001;24:239-62. doi: 10.1146/annurev.neuro.24.1.239. Annu Rev Neurosci. 2001. PMID: 11283311 Review.
-
Neuroimmunology of the paraneoplastic neurological degenerations.Curr Opin Immunol. 2004 Oct;16(5):616-22. doi: 10.1016/j.coi.2004.07.009. Curr Opin Immunol. 2004. PMID: 15342008 Review.
-
Onconeural versus paraneoplastic antigens?Curr Med Chem. 2007;14(23):2489-94. doi: 10.2174/092986707782023668. Curr Med Chem. 2007. PMID: 17979702 Review.
Cited by
-
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.Oncologist. 2016 Aug;21(8):910-21. doi: 10.1634/theoncologist.2015-0523. Epub 2016 Jun 27. Oncologist. 2016. PMID: 27354668 Free PMC article. Review.
-
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9824-9. doi: 10.1073/pnas.171320598. Proc Natl Acad Sci U S A. 2001. PMID: 11504947 Free PMC article.
-
[Paraneoplastic syndrome in renal cell carcinoma].Urologe A. 2007 Jan;46(1):45-8. doi: 10.1007/s00120-006-1269-2. Urologe A. 2007. PMID: 17186189 Review. German.
-
Rapid-onset paraneoplastic cerebellar degeneration successfully treated by radiotherapy and tumorectomy.Int Cancer Conf J. 2022 Aug 4;12(1):19-23. doi: 10.1007/s13691-022-00569-4. eCollection 2023 Jan. Int Cancer Conf J. 2022. PMID: 36605832 Free PMC article.
-
Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.J Clin Invest. 2009 Jul;119(7):2042-51. doi: 10.1172/JCI36131. Epub 2009 Jun 8. J Clin Invest. 2009. PMID: 19509467 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical